Handbook of Clinical medicine
KEYWORDS: patient, disease, patients, history, pain, heart, symptoms, ask, time, treatment, risk, examination, aortic, iinnddbb, pulse

generally recommended if >2cm in size). Surgery may be avoided in MEN1, as adeno- mas are often multiple, and metastatic disease is rare. If well-diff erentiated (G1 and G2) somatostatin analogues may be 1st-line and chemotherapy with streptozotocin (if available) + doxorubicin/5-FU is 2nd-line. In G3, etoposide + cisplatin is possible.69 Selective embolization may be done for hepatic metastases. Prognosis: 5yr survival: 80% if single resectable lesion, ~20% with hepatic metastases. Screen all patients for MEN1. Robert M Zollinger, 1903–1992; Edwin H Ellison, 1918–1970 (US surgeons) __OOHHCCMM__1100ee..iinnddbb 771166 0022//0055//22001177 1199::0088 semordnys suomynopE 717 Fig 15.23 OctreoScan in patient with metastatic MEN 1 gastrinoma. Solitary hepatic metastatic deposit (thin arrow), gastric neuroendocrine tumour (thick arrow). Reproduced from Wass et al., Oxford Textbook of Endocrinology and Diabetes, 2011, with permission from Oxford University Press. Epilogue 25% of patients with rare diseases have to wait from 5–30 years for a diagnosis. 40% are misdiagnosed resulting in inappropriate drugs or psychological treat- ments—eg 20% of people with Ehlers–Danlos syndrome (p149) had to consult over 20 doctors before the diagnosis was made,70 causing understandable loss of confi dence in our profession. Lack of appropriate referral and rejection because of disease complexity are common problems. Let
